Is CorMedix Inc. (CRMD) a Buy, Sell, or Hold?
CorMedix Inc.
NASDAQ:CRMD
$8.42 USD
$0.15 (1.81%)
- Volume
- 640.99K
- Average Volume
- 1.33M
- Market Capitalization
- $660.56M
- P/E Ratio
- 3.54
- Dividend Yield
- 0.00%
- Price Target
- $13.00
- Year High
- $14.96
- Year Low
- $6.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.98
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joseph Todisco |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRMD |
| CUSIP | 21900C308 |
| CIK | 0001410098 |
| Web | https://www.cormedix.com |
| Phone | 908 517 9500 |
| Currency | USD |
| Employees | 191 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.34 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.98 |
| Quick Ratio | 2.74 |
| Cash Ratio | 1.38 |
Sales & Book Value
| Annual Sales | $311.71M |
| Price / Sales | 1.65 |
| Cash Flow | 2.47 |
| Price / Cash Flow | 3.36 |
| Price / Book | 1.53 |
Price Target and Rating
| Average Stock Price Forecast | $13.00 |
| High Stock Price Forecast | $14.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -35.23% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.04 |
| Trailing P/E Ratio | 3.54 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $163.06M |
| Net Margin | 45.25% |
| Pretax Margin | 46.25% |
| Return on Equity | 50.38% |
| Return on Assets | 22.19% |
Financials Score
| AltmanZ Score | 2.42 |
| Piotroski Score | 4.00 |
| Working Capital | 254.34M |
| Total Assets | 815.64M |
| Ebit | 187.79M |
| Market Cap | 652.72M |
| Total Liabilities | 378.59M |
Poll Results
About CorMedix Inc. (NASDAQ:CRMD) Stock
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey. ...
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
2026-06-30 12:10:19
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
2026-06-30 12:10:17
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
2026-06-30 12:06:05
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
2026-06-08 08:30:00
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
2026-05-27 13:36:18
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
2026-05-22 06:05:51
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath utilization through changes in federal reimbursement.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
2026-05-15 11:16:18
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
2026-05-15 08:30:00
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:
Frequently Asked Questions
-
What is the current CorMedix Inc. (CRMD) stock price?
-
CorMedix Inc.(NASDAQ:CRMD) stock price is $8.42 in the last trading session. During the trading session, CRMD stock reached the peak price of $14.96 while $6.13 was the lowest point it dropped to. The percentage change in CRMD stock occurred in the recent session was 1.81% while the dollar amount for the price change in CRMD stock was $0.15.
-
CRMD's industry and sector of operation?
-
The NASDAQ listed CRMD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRMD?
-
Peter Sullivan BCOP | Senior Vice President of Market Access
Tushar Mukherjee | Senior Vice President & Head of Technical Operations
Joseph Todisco | CEO & Chairman of the Board of Directors
Michael Seckler | Executive Vice President & Chief Commercial Officer
Elizabeth Hurlburt | Executive Vice President, Chief Operating Officer & Chief Integration Officer -
How many employees does CRMD have?
-
Number of CRMD employees currently stands at 191. CRMD operates from 300 Connell Drive, Berkeley Heights, NJ 07922, US.
-
Link for CRMD official website?
-
Official Website of CRMD is: https://www.cormedix.com
-
How do I contact CRMD?
-
CRMD could be contacted at phone #908 517 9500 and can also be accessed through its website. CRMD operates from 300 Connell Drive, Berkeley Heights, NJ 07922, US.
-
How many shares of CRMD are traded daily?
-
The average number of CRMD shares traded daily for last 3 months was 1.33M.
-
What is the market cap of CRMD currently?
-
The market value of CRMD currently stands at $660.56M with its latest stock price at $8.42